DB:7D2

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally.


Snowflake Analysis

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Sedana Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 7D2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.7%

7D2

4.9%

DE Medical Equipment

2.0%

DE Market


1 Year Return

142.0%

7D2

38.7%

DE Medical Equipment

-2.6%

DE Market

Return vs Industry: 7D2 exceeded the German Medical Equipment industry which returned 38.7% over the past year.

Return vs Market: 7D2 exceeded the German Market which returned -2.6% over the past year.


Shareholder returns

7D2IndustryMarket
7 Day5.7%4.9%2.0%
30 Day20.6%14.8%8.4%
90 Day79.5%21.6%-7.3%
1 Year142.0%142.0%40.4%38.7%-1.0%-2.6%
3 Yearn/a134.7%129.8%-6.6%-13.9%
5 Yearn/a294.1%279.7%1.1%-11.7%

Price Volatility Vs. Market

How volatile is Sedana Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sedana Medical undervalued compared to its fair value and its price relative to the market?

45.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 7D2 (€24.3) is trading below our estimate of fair value (€44.9)

Significantly Below Fair Value: 7D2 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 7D2 is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: 7D2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 7D2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 7D2 is overvalued based on its PB Ratio (10x) compared to the DE Medical Equipment industry average (5x).


Next Steps

Future Growth

How is Sedana Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

119.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7D2 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 7D2 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 7D2's is expected to become profitable in the next 3 years.

Revenue vs Market: 7D2's revenue (35.7% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: 7D2's revenue (35.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 7D2's Return on Equity is forecast to be low in 3 years time (2.6%).


Next Steps

Past Performance

How has Sedana Medical performed over the past 5 years?

-66.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 7D2 is currently unprofitable.

Growing Profit Margin: 7D2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 7D2 is unprofitable, and losses have increased over the past 5 years at a rate of -66.7% per year.

Accelerating Growth: Unable to compare 7D2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7D2 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.2%).


Return on Equity

High ROE: 7D2 has a negative Return on Equity (-2.05%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sedana Medical's financial position?


Financial Position Analysis

Short Term Liabilities: 7D2's short term assets (SEK474.4M) exceed its short term liabilities (SEK24.3M).

Long Term Liabilities: 7D2 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 7D2 is debt free.

Reducing Debt: 7D2 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7D2 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 7D2 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Sedana Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 7D2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 7D2's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7D2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7D2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 7D2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Christer Ahlberg (48yo)

3.25yrs

Tenure

kr2,095,100

Compensation

Mr. Christer Ahlberg serves as a Chief Executive Officer of Sedana Medical AB (publ) since February 1, 2017. He serves as President of Sedana Medical AB (publ) since February 2017. Mr. Ahlberg has many yea ...


CEO Compensation Analysis

Compensation vs Market: Christer's total compensation ($USD216.49K) is below average for companies of similar size in the German market ($USD1.08M).

Compensation vs Earnings: Christer's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Christer Ahlberg
President & CEO3.25yrskr2.10m1.47% SEK7.9m
Maria Engström
Chief Financial Officer3.25yrsno data0.19% SEK1.1m
Peter Sackey
Chief Medical Officer2.33yrsno data0.21% SEK1.1m

3.3yrs

Average Tenure

48yo

Average Age

Experienced Management: 7D2's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sten Gibeck
Independent Director15.33yrskr50.00k6.73% SEK36.4m
Ola Magnusson
Independent Director15.33yrskr50.00k0.17% SEK925.1k
Thomas Eklund
Independent Chairman of the Board6.33yrskr283.30k1.83% SEK9.9m
Bengt Julander
Independent Director9.33yrskr50.00kno data
Eva Walde
Independent Director2yrskr100.00k0.014% SEK76.1k
Christoffer Rosenblad
Directorno datano datano data

9.3yrs

Average Tenure

66yo

Average Age

Experienced Board: 7D2's board of directors are considered experienced (9.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 7D2 insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.


Top Shareholders

Company Information

Sedana Medical AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sedana Medical AB (publ)
  • Ticker: 7D2
  • Exchange: DB
  • Founded: 2005
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr5.707b
  • Listing Market Cap: kr541.169m
  • Shares outstanding: 22.74m
  • Website: https://www.sedanamedical.com

Number of Employees


Location

  • Sedana Medical AB (publ)
  • VendevAegen 87
  • Danderyd
  • Stockholm County
  • 182 32
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SEDANAOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2017
7D2DB (Deutsche Boerse AG)YesShare CapitalDEEURJun 2017

Biography

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers AnaConDa and AnaConDa-S, which are disposable medical devices that enables the administration of volatile anesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb-S, a filter containing activated carbon for the removal of waste anaesthetic gases; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb and FlurAbsorb-S mount to hold the filter during scavenging of anesthetic gas. It also provides isoflurane/sevoflurane and Sevorane QuickFil filling adaptors; gas sampling lines to prevent anaesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anaesthetic gas measuring line and the water trap of the gas monitor. In addition, the company develops IsoConDa, a therapy for inhalation sedation in intensive care. Sedana Medical AB (publ) was founded in 2005 and is headquartered in Danderyd, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/27 05:47
End of Day Share Price2020/05/26 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.